Wednesday, July 29, 2015

TECHNICAL ANALYSIS OF GLENMARK & DAILY CHART

FUTURE :
“BULLISH GLENMARK ABOVE 950  TGT 975/1000”
 “BEARISH GLENMARK BELOW 940  TGT 928/910”
DAILY RESISTANCE: 979, 1005, 1056, 1107
DAILY PIVOT POINT: 954
DAILY SUPPORT:  928, 903, 852, 801
DAILY CHATS



















UPCOMING RESULT: GLENMARK
After showing correction from the higher level, now stock is trading in short term recovery phase, it is likely to continue the upside move in near term with the crossing of the resistance level of 1005 as the stock is managing to sustain above the level of 979. One may get the targets of 1056,1107. it is likely to show correction with the breach of the support level of 940, where one may initiate the short position in it for the targets of 928/910
Simple Moving Averages
Days
BSE
NSE
30
1022.88
1023.08
50
961.66
961.88
150
856.00
856.21
200
833.29
833.45
PROFIT SUMMARY FOR 29 JULY 2015


The  Sensex ended the day on positive note and was up over 100 points at 27,563.Nifty closed 38 points up at 8,375. following profit taking that were restricting any major gains and consistency in the markets.The volatility was also owing to the July F&O series expiry on Thursday, with rollovers picking up. However, markets were getting some support with some positive cues from the regional peers, as the Chinese market was trading flat after government measure provided some stability to the unruly stock market. Top three Indian IT majors TCS, Wipro and Infosys together added 12,187 employees in the June quarter. This is a nearly 68% net increase over the same quarter last year. Wipro and Infosys ended up 1.4-2% each. However, TCS ended flat with negative bias.L&T ended up 1.8% ahead of its April-June earnings tomorrow. BHEL was up 2.4%.HDFC gained 1.2% after the mortgage lender's loan book jumped 13.6% to Rs 2,31,224 crore at the end of June quarter compared to Rs 2,03,384 crore a year ago.Other Sensex gainers which gained include, ICICI Bank, Tata Motors, Maruti Suzuki, Lupin and Sun Pharma among others.

No comments:

Post a Comment